Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 8/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | ROR1 | Q01973 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907249 | 0.75 | KIT (0.48) | ABL1KITDDR1CSF1RROR1 | |
| SCHEMBL15907263 | 0.73 | KIT (0.40) | ABL1KITDDR1CSF1RROR1 | |
| SCHEMBL15907256 | 0.71 | ABL1 (0.58) | ABL1KITDDR1CSF1RCYP3A4 | |
| SCHEMBL15907301 | 0.69 | KDR (0.36) | ABL1CSF1RLCKKDRTEK | |
| SCHEMBL15800773 | 0.69 | KIT (0.67) | ABL1KITDDR1CSF1RCYP3A4 | |
| SCHEMBL15907245 | 0.68 | ABL1 (0.43) | ABL1KITDDR1 | |
| SCHEMBL15907316 | 0.68 | CSF1R (0.35) | KITDDR1CSF1RLCKKDR | |
| SCHEMBL15907251 | 0.66 | ALDH1A1 (0.43) | POLBKITDDR1KDR | |
| SCHEMBL18323152 | 0.66 | GRM4 (0.36) | ABL1POLBKDR | |
| SCHEMBL18323134 | 0.65 | BCAT2 (0.42) | KITDDR1CSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | ABL1 1/4885POLB 2184/4885KIT 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.